CHRONIC LYMPHOCYTIC LEUKEMIA

This study tested a personalized geriatric optimization plan (GO!) in 30 patients over 60 receiving a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see if these changes …

This study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…

This study tested the safety of an experimental drug called cirmtuzumab in 3 people with chronic lymphocytic leukemia (CLL) who had received the drug before. The drug targets a protein on cancer cells while sparing most healthy cells. The goal was to see if giving the drug for 6 …

This study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers (like lymphoma and leukemia) or advanced solid tumors. The main goals were to find safe doses and check for side effects. The trial was completed, but…

This study tested whether giving the drug ibrutinib early to people with chronic lymphocytic leukemia (CLL) who have no symptoms but are at high risk for the disease getting worse could help them achieve remission. Twenty-three participants took ibrutinib for up to 24 months. The…

This early-phase study tested adding the cholesterol drug pitavastatin to the standard cancer drug venetoclax for people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Only 6 people took p…

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…

This study tested a medicine called Panzyga in 247 people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The goal was to see if regular infusions of Panzyga could prevent serious infections. Participants received either Panzyga or a placebo, and resear…

This study tested a combination of three drugs—ibrutinib, fludarabine, and pembrolizumab—in 15 people with high-risk or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if the combination could achieve a complete resp…

This study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…

This study tested a combination of two drugs, ibrutinib and obinutuzumab, in 32 older adults (65+) with untreated chronic lymphocytic leukemia (CLL) who could not take chemotherapy. The goal was to see if the combo could safely reduce the amount of cancer cells in the body. Resul…

This study tested a combination of two drugs, idelalisib and ofatumumab, in 27 adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well the drugs worked together to shrink or control the cancer. Particip…

This early-phase study tested a new approach for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T cells) and added a special receptor (a…

This study tested whether using a patient's own stem cells (autologous transplant) after high-dose chemotherapy could help people with untreated chronic lymphocytic leukemia (CLL) live longer without the disease getting worse. The trial included 241 adults aged 18 to 65 with stag…

This early-phase study tested an experimental therapy called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The main goal was to find the safest dose and see if the treatment could shrink tumors. B…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by donor stem cells to help destroy c…

This study tested a combination of two drugs, ofatumumab and lenalidomide, along with a steroid, in 45 people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if this treatment could make cancer disappear or shrink signifi…

This study tested a two-step treatment for people with untreated chronic lymphocytic leukemia (CLL). First, participants received a standard chemo-immunotherapy combination (bendamustine and rituximab), followed by a year of the oral targeted drug venetoclax. The goal was to see …

This study tested whether the drug ibrutinib, combined with standard vaccines, can delay disease progression in people with early-stage, high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have no symptoms yet. Forty-two participants received ibru…

This early-phase study tested a combination of two drugs, acalabrutinib and obinutuzumab, in 69 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination was safe and could shrink or eliminate cancer. Participants included tho…

This study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a specific genetic change (deletion 17p). The goal was to see how well the drug controls the cancer. Participants took acalabrutinib pil…

This early-stage study tested a new drug called odronextamab (REGN1979) in 200 adults with B-cell blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia that had stopped responding to standard treatments. The goal was to check the drug's safety and find the righ…

This study tested a daily medication called acalabrutinib in 552 adults with chronic lymphocytic leukemia (CLL). Participants included those newly diagnosed, those whose cancer returned or didn't respond to treatment, and those who had previously taken a similar drug. The main go…

This early-phase trial tested a new cell therapy called IOV-2001 in 7 people whose chronic lymphocytic leukemia or small lymphocytic lymphoma had stopped responding to standard treatments like ibrutinib. The therapy uses the patient's own immune cells, which are collected, proces…

This study looked at whether giving vitamin D supplements to people with newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia who have low vitamin D levels could improve their outcomes. About 197 participants received either a low or high dose of vitamin D alongsi…

This study tested whether regular phone calls from a nurse could help people with chronic lymphocytic leukemia (CLL) manage side effects and stick to their full chemotherapy plan. Sixty patients starting a common chemo combo (FCR) received the calls. The goal was to see if this s…

This study looked at how often people with chronic lymphocytic leukemia or multiple myeloma face money problems because of their treatment. About 218 patients and their doctors answered surveys about costs and available help. The goal was to measure how common financial difficult…

This study looked for biological markers that could predict early on whether the drug ibrutinib would stop working in people with a high-risk form of chronic lymphocytic leukemia (CLL) that has a TP53 mutation. Researchers followed 56 adults with CLL who were starting ibrutinib t…

This study tracked 89 Japanese adults with chronic lymphocytic leukemia (CLL) who took venetoclax, sometimes with rituximab, for 24 months. Researchers measured how many patients had undetectable minimal residual disease (uMRD), a sign of deep remission. The goal was to understan…